Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Clinical trial to study the effectiveness of oxaliplatin in treating patients who have locally advanced or metastatic colorectal cancer that has been previously treated.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Treatment Access Program With Oxaliplatin for Previously Treated Colorectal Cancer Patients|
|Study Start Date:||January 2002|
|Study Completion Date:||March 2004|
|Primary Completion Date:||August 2003 (Final data collection date for primary outcome measure)|
- Provide oxaliplatin for patients with previously treated locally advanced or metastatic colorectal cancer who have exhausted all approved therapies for colorectal cancer.
OUTLINE: This is a multicenter, Treatment Access Program study.
Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed for at least 30 days.
PROJECTED ACCRUAL: Approximately one patient per site per month will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00040820
|United States, New York|
|Roswell Park Cancer Institute|
|Buffalo, New York, United States, 14263-0001|
|Study Chair:||Milind Javle, MD||Roswell Park Cancer Institute|